The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

Blood
Claire GreenRosemary E Gale

Abstract

Mutations in the isocitrate dehydrogenase gene (IDH1) were recently described in patients with acute myeloid leukemia (AML). To investigate their prognostic significance we determined IDH1 status in 1333 young adult patients, excluding acute promyelocytic leukemia, treated in the United Kingdom MRC AML10 and 12 trials. A mutation was detected in 107 patients (8%). Most IDH1(+) patients (91%) had intermediate-risk cytogenetics. Mutations correlated significantly with an NPM1 mutation (P < .0001) but not a FLT3/ITD (P = .9). No difference in outcome between IDH1(+) and IDH1(-) patients was found in univariate or multivariate analysis, or if the results were stratified by NPM1 mutation status. However, when stratified by FLT3/ITD status, an IDH1 mutation was an independent adverse factor for relapse in FLT3/ITD(-) patients (P = .008) and a favorable factor in FLT3/ITD(+) patients (P = .02). These results suggest that metabolic changes induced by an IDH1 mutation may influence chemoresistance in a manner that is context-dependent.

References

Jul 2, 2008·Haematologica·Konstanze Döhner, Hartmut Döhner
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Feb 21, 2009·The New England Journal of Medicine·Craig B Thompson
Apr 21, 2009·International Journal of Cancer. Journal International Du Cancer·Mi Ran KangSug Hyung Lee
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katharina WagnerJürgen Krauter
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claire L GreenRosemary E Gale

❮ Previous
Next ❯

Citations

Mar 21, 2013·Acta Neuropathologica·Craig Horbinski
Apr 27, 2013·Leukemia·A M VannucchiA Tefferi
Aug 18, 2012·Nature Reviews. Cancer·Alan H ShihRoss L Levine
Jul 20, 2012·Genetic Testing and Molecular Biomarkers·Yiqun ZhangJianxiang Wang
Sep 28, 2012·Current Opinion in Oncology·Gail J Roboz
Feb 6, 2013·Current Opinion in Hematology·Mathijs A Sanders, Peter J M Valk
Dec 17, 2011·Applied Immunohistochemistry & Molecular Morphology : AIMM·Richard ByersScott J Rodig
Aug 22, 2012·Acta Haematologica·Milos KuzmanovicMilica Colovic
Dec 14, 2011·Hematology·Hartmut Döhner, Verena I Gaidzik
Jan 15, 2014·Current Opinion in Hematology·Shira N DinnerJessica K Altman
Mar 25, 2014·Current Hematologic Malignancy Reports·Bhavana Bhatnagar, Ramiro Garzon
Mar 13, 2014·Current Hematologic Malignancy Reports·Mohamad K Khasawneh, Omar Abdel-Wahab
Aug 12, 2014·Biochemical and Biophysical Research Communications·Shlomzion Aumann, Omar Abdel-Wahab
Aug 5, 2015·Journal of Clinical Medicine·Sophia Yohe
Jan 21, 2016·Expert Review of Hematology·Hsin-An Hou, Hwei-Fang Tien
Jan 9, 2015·Drug Metabolism Reviews·Lisa Pleyer, Richard Greil
Mar 6, 2013·Surgical Pathology Clinics·Craig Horbinski
Aug 25, 2012·Human Pathology·Dinesh RakhejaWeina Chen
Nov 19, 2011·Hematology/oncology Clinics of North America·Omar Abdel-WahabRoss L Levine
Aug 29, 2013·Protein & Cell·Grace L PeloquinAmir T Fathi
Feb 15, 2011·Leukemia Research·Yiqun ZhangJianxiang Wang
Mar 5, 2016·Surgical Pathology Clinics·Valentina Nardi, Robert P Hasserjian
Dec 20, 2011·American Journal of Hematology·Elihu H Estey
Nov 11, 2011·American Journal of Hematology·Hady GhanemImad A Tabbara
Dec 18, 2012·British Journal of Haematology·Yishai Ofran, Jacob M Rowe
Sep 29, 2015·Archives of Pathology & Laboratory Medicine·Michael L Wang, Nathanael G Bailey
Mar 20, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Simon Blechman ZeichnerRobert John Poppiti
Jun 30, 2015·Experimental Hematology·Anna ErikssonSören Lehmann
Apr 30, 2015·BMC Genomics·Asad Muhammad IlyasFarid Ahmed

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.